


April 14-16, 2025 | Boston, MA




4th Annual LNP Formulation & Process Development Summit

Successfully Fast-Track your LNPs from Concept to Market

Your Comprehensive Roadmap to Discover, Formulate & Manufacture Highly Stable & Selective LNPs for All Therapeutically Valuable Payloads to Ensure Safety & Efficacy of Your Drug Product for Patients

50+ World-Class Speakers, Including:



Pieter Cullis
Professor
University of British Columbia



Annette Bak
Head, Advanced Drug Delivery
AstraZeneca



Magali Hickey
Head of LNP Process Development, Delivery
Moderna



Sanyogita Puri
Senior Director, Head, Non-Viral Delivery
Novo Nordisk



Luis Santos
Senior Director
Prime Medicine



George Dakwar
Director, Formulation Platform
CureVac



Saswata Karmakar
Director, Chemistry
Sanofi



Peng Zhang
Principal Scientist
US Pharmacopeia



Bindu Varghese
Executive Director, Research
Carisma Therapeutics



300+
LNP Expert Attendees



50+
LNP Industry Trailblazers Presenting Insights



3
Tracks of Parallel Talks for You & Your Team



3
Days of Unparalleled New Data

SAVE \$800 BY REGISTERING BEFORE FRIDAY, DECEMBER 13

CONTENTS

INTRODUCTION

AGENDA AT A GLANCE

YOUR EXPERT SPEAKERS

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PRICING & DISCOUNTS



REGISTER NOW

Lead Partner



+ (1) 617 455 4188

@ info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

LNP Development



Welcome to the 4th LNP Formulation & Process Development Summit

With **Novo Nordisk's** latest \$600M deal for lipid nanoparticle technology for genetic medicines, and **700+ lipid-based vehicles in pre-clinical and clinical pipelines**, the LNP continues to dominate as the carrier of choice for vaccines, genomic medicine, *in vivo*-CAR-T, protein replacement therapies and beyond, unleashing its power across novel applications towards patient benefit.

Serving as the largest one-stop-shop for LNP industry leaders, this summit will dive deep across the end-to-end drug development value chain to aid the progress of safer and more efficacious LNP pipelines in 2025. Returning to Boston with a more comprehensive program than ever before, we are excited to showcase **3 jam-packed days** and a refreshed **three track agenda**. Here's what's new for 2025...



Showcasing more scientific innovation than ever, expand across three parallel tracks of **Analytical Development & Characterization, Formulation & Delivery** and **Process Development & Manufacturing** to optimize your LNP development from research to clinical and commercial scale with GMP compliance



Hear brand new insights and exclusive data, with over 85% brand new speakers from key stakeholders, including the likes of **Carisma Therapeutics, Moderna, Yoltech Therapeutics, Takeda, ReCode Therapeutics, Sail Biomedicines** and more, as we consider re-engineering LNPs with antibody conjugates and novel ionizable lipids to effectively deliver cargo with cell-specificity



Join expert-led discussions on designing efficient lipid libraries and high throughput screening methods as well as boosting your network and capitalizing on forging new alliances in the LNP industry, to **achieve collaborations for advancing best-in-class customized LNPs for specific applications**

Curated with expert minds from **AstraZeneca, Moderna, Novo Nordisk** and **University of British Columbia**, this meeting is an unmissable chance to join **300+ Discovery, Formulation, LNP Delivery**, and **CMC experts** to supercharge your LNP development and stay ahead of the curve, achieving better stability, safety and scalability for all LNPs to achieve unmet clinical needs.

Meet the Expert Scientific Advisory Board



For the first time, the **LNP Formulation & Process Development Summit** partnered with a Scientific Advisory Board to direct and advise the curation of a world-class meeting



Annette Bak
Head, Advanced Drug Delivery
AstraZeneca



Magali Hickey
Head, LNP Process Development
Moderna



Sanyogitta Puri
Senior Director, Head, Non-Viral Delivery
Novo Nordisk



Pieter Cullis
Professor
University of British Columbia

Introducing...

The 1st LNP Awards Ceremony

The awards has been curated to commend excellence in LNP research. It is a privilege to celebrate recent successes, long-term commitment to the field, and upcoming pioneers who have gone above and beyond to ensure the continued success of the field.

The Award Categories:



Pieter Cullis Award



LNP Impact Award



LNP Innovation Award



LNP Solution Provider Award

SAVE \$800 BY REGISTERING BEFORE FRIDAY, DECEMBER 13

CONTENTS

INTRODUCTION

AGENDA AT A GLANCE

YOUR EXPERT SPEAKERS

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PRICING & DISCOUNTS



REGISTER NOW

2

+ (1) 617 455 4188

@ info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

in LNP Development




Your Ultimate LNP Roadmap from Discovery to Market

4th Annual LNP Formulation & Process Development Summit
April 14-16, 2025, Boston, MA

SAVE \$800 BY REGISTERING BEFORE FRIDAY, DECEMBER 13

Join us as we cover the **end-to-end** development of LNPs for different payloads and therapeutic applications, from **discovery**, **analytics**, and **formulation** to **clinical** and **commercial manufacturing**, to achieve safe, stable and compliant LNPs for treating a wide array of disease.



CONTENTS

INTRODUCTION

AGENDA AT A GLANCE

YOUR EXPERT SPEAKERS

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PRICING & DISCOUNTS



REGISTER NOW

5 Reasons Not to Miss Out in 2025

4th Annual LNP Formulation & Process Development Summit
April 14-16, 2025, Boston, MA

SAVE \$800 BY REGISTERING BEFORE FRIDAY, DECEMBER 13




Industry Leaders' Panel Discussion

Navigate challenges of toxicity, extrahepatic delivery and scaling-up to accelerate your LNP pipelines by acquiring first-hand insights from **University of British Columbia, Alnylam, AstraZeneca, Moderna & Novo Nordisk**




 **Pieter Cullis**
Professor
University of British Columbia

 **Muthiah (Mano) Manoharan**
Senior Vice President, Innovation Chemistry & Alnylam Distinguished Scientist
Alnylam Pharmaceuticals

 **Annette Bak**
Head, Advanced Drug Delivery
AstraZeneca

 **Magali Hickey**
Head, LNP Process Development
Moderna

 **Sanyogitta Puri**
Senior Director, Head, Non-Viral Delivery
Novo Nordisk



Optimizing Extrahepatic Delivery for Treating More Diseases

Hear exclusive insights from the likes of **Sanofi, Biogen & Editas Medicine** to develop innovative ionizable lipids and targeted LNPs to achieve extrahepatic delivery for treating a wider landscape of diseases.

Showcasing novel LNP formulations for the following targets and applications:

Muscle



Brain



Lung



Bone Marrow



Cell Therapy



Gene Therapy



LNPs for Cell & Gene Therapy Delivery

Uncover the potential of LNPs for delivering payloads beyond mRNA. Hear brand-new insights from **Bristol Myers Squibb, Prime Medicine, Carisma Therapeutics & Yoltech Therapeutics** to enhance delivery of cell therapy and gene editing payloads

 **Melissa Hanson**
Senior Principal Scientist
Bristol Myers Squibb

 **Luis Santos**
Senior Director
Prime Medicine

 **Bindu Varghese**
Executive Director, Research
Carisma Therapeutics

 **Zi Jun Emma Wang**
Chief Technology Officer
Yoltech Therapeutics



Mitigate Patent Risks for More Compliant LNPs

Join an interactive, deep dive workshop led by **Rothwell Figg** to de-risk patent infringements. Gain insights into robust due diligence and freedom to operate strategies that ensure you have strong and compliant IP for your LNP vehicles

 **Daniel Shores**
Partner
Rothwell Figg



The Future: Next Generation LNPs to Achieve Specific Delivery

Advance nucleic acid delivery with next-generation LNPs. Hear from **Entos Pharmaceuticals & Zipcode Bio** as they unlock the newest and hottest LNP delivery vehicles for enabling tissue-specific delivery of payloads to the liver and beyond



 **John Lewis**
Chief Executive Officer
Entos Pharmaceuticals

 **Jie Su**
Head, Formulation
Zipcode Bio

CONTENTS

INTRODUCTION

AGENDA AT A GLANCE

YOUR EXPERT SPEAKERS

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PRICING & DISCOUNTS



REGISTER NOW

Agenda at a Glance

SAVE \$800 BY REGISTERING BEFORE FRIDAY, DECEMBER 13

PRE-CONFERENCE DAY Monday, April 14

Track A: LNP 101 Day | **Track B & C: Workshop Day**

Deep Diving into the History, Early Successes & Key Components of LNPs

Morning Networking Break

Workshop A: Improving Lipid Libraries & High Throughput Screening Strategies

Workshop C: De-risking LNP CMC Development to Improve GMP Manufacturing **NEW**

Delving into Fundamental Analytical, Formulation & Manufacturing Strategies for LNPs

Lunch & Networking Break

Workshop B: Evaluating Brain, Lung & Bone Marrow Targeting Strategies with Cell Specific LNPs

Workshop D: Navigating IP Challenges to Enable Freedom to Operate & Mitigate Infringement Risk **NEW**

Unleashing the Potential of LNPs to Treat Various Diseases

Lunch & Networking Break

End of Pre-Conference Day

CONFERENCE DAY ONE Tuesday, April 15

Navigating LNPs Largest Bottlenecks of Extrahepatic Delivery, Toxicity & Scale-Up **NEW**

Morning Break & Speed Networking

Track A: Analytical Development & Characterization	Track B: Formulation & Delivery	Track C: Process Development & Manufacturing
Accomplishing Deeper Characterization with Improved Particle Analysis	Showcasing Successful Strategies to Reduce Liver Clearance	Optimizing Process Development to Develop Late-Stage Manufacturing Strategies

Lunch & Networking Break

Assessing Quality, Stability & Encapsulation Efficiency of LNPs	Achieving Muscle-Selective Delivery Through Customized Ionizable Lipids	Identifying Key Considerations to Scale Up LNP Manufacturing
--	--	---

Afternoon Networking Break & Poster session

Evaluating Lipid Properties & Excipient Quality for Advancing High Quality & Stable LNPs	Optimizing <i>In Vitro</i> to <i>In Vivo</i> Translation of LNPs	Accelerating LNP Production with Advanced Manufacturing Strategies
---	---	---

LNP Awards 2025 & Drinks Reception

CONFERENCE DAY TWO Wednesday, April 16

Partnership, Collaboration & Licensing **NEW**

Morning Networking Break

Track A: Analytical Development & Characterization	Track B: Formulation & Delivery	Track C: Process Development & Manufacturing
Improving LNP Potency Using Cryo-EM & Assay Methods	Unlocking LNP Formulations with Improved Encapsulation of Gene Editors	Leveraging Strategies for Improving Stability & Storage of LNPs

Lunch & Networking Break

Creating a Clear Roadmap for Analytical Development of LNPs	Illuminating the Potential of LNPs for Gene Editors & Delving into Genuine Clinical Trial	Accomplishing LNP Thermostability for Improved Storage to Enable Global Availability
--	--	---

Afternoon Networking Break

The Future of LNPs **NEW**

End of the 4th LNP Formulation & Process Development Summit 2025

CONTENTS

INTRODUCTION

AGENDA AT A GLANCE

YOUR EXPERT SPEAKERS

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PRICING & DISCOUNTS



REGISTER NOW

Your Expert Speakers

10th Annual LNP Formulation & Process Development Summit

April 14-16, 2025, Boston, MA

SAVE \$800 BY REGISTERING BEFORE FRIDAY, DECEMBER 13

World-Class Scientific Advisory Board




Annette Bak
Head, Advanced Drug Delivery
AstraZeneca



Magali Hickey
Head, LNP Process Development
Moderna



Sanyogitta Puri
Senior Director, Head, Non-Viral Delivery
Novo Nordisk



Pieter Cullis
Professor
University of British Columbia

Key Opinion Leaders from Biopharma & Academia



Bo Ying
Chief Executive Officer
Abogen Biosciences



Muthiah (Mano) Manoharan
Senior Vice President, Innovation Chemistry & Alnylam Distinguished Scientist
Alnylam Pharmaceuticals



Shengshuang Zhu
Senior Principal Scientist
Arbor Biotechnologies



Anubhav Arora
Director, Chemistry, Manufacturing & Controls
Apellis Pharmaceuticals



Yan Xia
Head, Nanotechnology Formulations
Axelyx



Melissa Hanson
Senior Principal Scientist
Bristol Myers Squibb



Mandana Borna
Head, Oligonucleotide Drug Product Development
Biogen



Bindu Varghese
Executive Director, Research
Carisma Therapeutics



David Chu
Senior Director, Analytical Operations
Capstan Therapeutics



George Dakwar
Director, Formulation Platform
CureVac



Jieni Xu
Head, Delivery Science
Editas Medicine



Qook Lee
Research Advisor
Eli Lilly & Co



John Lewis
Chief Executive Officer
Entos Pharmaceuticals



Swathi Pullagurta
Senior Scientist
Gritstone Bio



Hui Li
Research & Development Director
Innorna



Jivan Yewle
Director, Non-Viral Delivery
Mammoth Biosciences

CONTENTS

INTRODUCTION

AGENDA AT A GLANCE

YOUR EXPERT SPEAKERS

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PRICING & DISCOUNTS



REGISTER NOW

6

+ (1) 617 455 4188

info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

LNP Development



Key Opinion Leaders from Biopharma & Academia

5th Annual LNP Formulation & Process Development Summit

April 14-16, 2025, Boston, MA

SAVE \$800 BY REGISTERING BEFORE FRIDAY, DECEMBER 13



Jee-Young Park
Executive Director
MediciBIO



Thomas Cleveland
Physicist
NIST



Mansoor Amiji
University Distinguished Professor
Northeastern University



Sudhakar Garad
Global Head, Pre-formulation, Novel Delivery & Biopharmaceutics
Novartis




Benjamin Frempah
Director, Business Development
Omega Therapeutics



Ami Jo
Associate Director, Process Development
Omega Therapeutics



Sashini Wijetunge
Senior Scientist
Pfizer



Erika Jensen
Principal Scientist
Pfizer



Luis Santos
Senior Director
Prime Medicine



Rajesh Krishnan
Senior Director, Formulation
Providence Therapeutics



Rumpa Bhattacharjee
Senior Scientist II
ReCode Therapeutics



Alireza Nomani
Principal Scientist
Regeneron Pharmaceuticals



Amit Singh
Director, Delivery Discovery
RNA NewCo



Daniel Shores
Partner
Rothwell Figg



Alexey Popov
Vice President, Head, Process Development
Sail Biomedicines



Ching Kim Tye
Head, LNP Platform Development
Sanofi



Saswata Karmakar
Director, Chemistry
Sanofi



Srinivasulu Bandi
Director, External Manufacturing
Sail Biomedicines



Pintu Kanjilal
Scientist, LNP Discovery
Strand Therapeutics



Rui Zhang
Director
Stylus Medicine



Kanika Suri
Scientist
Takeda Pharmaceuticals



Katherine Cook
Scientist II
Tessera Therapeutics



Felipe Gazos Lopes
Associate Director, Analytical Development
Tessera Therapeutics



Zhengrong Cui
Professor
The University of Texas at Austin

CONTENTS

INTRODUCTION

AGENDA AT A GLANCE

YOUR EXPERT SPEAKERS

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PRICING & DISCOUNTS



REGISTER NOW

7

+ (1) 617 455 4188

@ info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

in LNP Development



Key Opinion Leaders from Biopharma & Academia

4th Annual
LNP Formulation &
Process Development Summit

April 14-16, 2025, Boston, MA

SAVE \$800 BY
REGISTERING
BEFORE
FRIDAY,
DECEMBER 13



Diane Burgess
Distinguished Professor
University of
Connecticut



Anni Chang
Senior Scientist II,
Excipients GSSD
US Pharmacopeia



Peng Zhang
Principal Scientist
US Pharmacopeia



Zi Jun Emma Wang
Chief Technology Officer
Voltech Therapeutics



Jie Su
Head, Formulation
Zipcode Bio

Pioneering Partners



“ LNP Formulation & Process Development Summit is a platform where scientists around the world with different expertise and perspectives gather to share the current progress in the field. ”

Scientist, LNP Discovery, **Strand Therapeutics**

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

8

+ (1) 617 455 4188

@ info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

in LNP Development



Pre-Conference Day - LNP 101 Day

Monday, April 14



Reviewing the Disease Applications of LNPs to Unleash their Full Potential for Treating a Large Variety of Patients

Annette Bak, Head, Advanced Drug Delivery, **AstraZeneca**



Getting up Speed on the Formulation Methods for Development of Traditional & Innovative LNPs

Kanika Suri, Scientist, **Takeda Pharmaceuticals**

Understanding new LNP formulations and challenges in the formulation process will aid in the advancement of analytical techniques and methods to better characterize mRNA/LNPs

Principal Scientist, **Pfizer**

4th Annual
**LNP Formulation &
Process Development Summit**
April 14-16, 2025, Boston, MA

Whether you have just started your LNP journey, created a new LNP platform or looking to get to grips with the basic foundations of LNP methods, formulations, and standards, the LNP 101 Day is your toolkit towards getting your knowledge up to speed on all the fundamental principles underpinning successful development of LNPs. Join your peers for an in-depth overview of the world of LNPs before delving into brand-new industry updates and data in the subsequent days.

9.00 AM Session

- ➔ Understand the evolution of LNPs by delving in their history
- ➔ Evaluate the 4 key components of LNPs and learn how these can be altered and improved
- ➔ Gain knowledge on fundamental strategies for analyzing, formulating and manufacturing traditional & innovative LNPs

1.00 PM LUNCH & NETWORKING

1.30 PM Session

- ➔ Uncover the potential of LNPs for delivering a range of payloads including mRNA, siRNA, CAR DNA, gRNA and beyond
- ➔ Delve into the novel applications of LNPs to achieve treatments for a wide range of diseases



SAVE \$800 BY
REGISTERING
BEFORE
FRIDAY,
DECEMBER 13

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW



+(1) 617 455 4188

info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

LNP Development



Pre-Conference Day - LNP 101 Day | Monday, April 14

4th Annual
LNP Formulation &
Process Development Summit
April 14-16, 2025, Boston, MA

SAVE \$800 BY
REGISTERING
BEFORE
FRIDAY,
DECEMBER 13



8.00 Check-In & Coffee With a Light Breakfast

8.50 Chair's Opening Remarks

Deep Diving into the History, Early Successes & Key Components of LNPs to Gain a Solid Foundation for Leveraging LNPs to Deliver Therapeutics & Vaccines

9.00 Delving into the History of Lipid Nanoparticles to Understand the Evolution of this Innovative Delivery Vehicle

- Deep diving into the discovery of LNPs to understand how they were initially invented
- Uncovering the initial formulations and purposes of LNPs through evaluation of the first patent filings which took place
- Reviewing academic and pharmaceutical progress of LNPs, including uncovering the development of the first FDA approved drug utilizing LNPs



Rui Zhang
Director
Stylus Medicine

NEW COMPANY

9.30 Uncovering the Roles of the Components in LNPs for Developing Stable Delivery Vehicles

- Evaluating the 4 components in LNPs; ionizable lipid, phospholipid, sterol and PEGylated phospholipid, for developing functional LNPs
- Exploring the potential of adding in a 5th component, such as polymers, to improve stability
- Improving targeting of LNPs with conjugates, peptides and more for enabling extrahepatic delivery



Jivan Yewle
Director, Non-Viral Delivery
Mammoth
Biosciences

NEW COMPANY

10.00 An mRNA-LNP Vaccine Platform that Elicits *In Vivo* Immune Response Against SARS-CoV-2 with Suitable Stability

- Details to be revealed



Alireza Nomani
Principal Scientist
Regeneron
Pharmaceuticals

NEW COMPANY



10.30 Morning Networking Break

Gaining Knowledge on the Fundamental Strategies for Successfully Analyzing, Formulating & Manufacturing Traditional & Innovative LNPs

11.30 Evaluating the Fundamental Analytical Methods for Characterizing & Identifying Effective LNPs with Good Encapsulation Efficiency, Morphology & Stability

- Delving into the current go-to analytical methods for understanding and characterizing LNPs
- Uncovering the limitations and benefits of each analytical method for better understanding of LNPs
- Utilizing Ribogreen assays and DLS to their full advantage for accurate measurement of particle size and encapsulation efficiency



Katherine Cook
Scientist II
Tessera Therapeutics

12.00 Getting up to Speed on the Formulation Methods for Development of Traditional & Innovative LNPs

- Delving into the past, present and future formulation development of LNPs
- Deep diving into the best formulation methods for reliably developing LNPs
- Revealing a successful roadmap for translating LNPs from concept to the clinic



Kanika Suri
Scientist
Takeda Pharmaceuticals

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

10

+ (1) 617 455 4188

@ info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

in LNP Development



Pre-Conference Day - LNP 101 Day | Monday, April 14

4th Annual
LNP Formulation &
Process Development Summit
April 14-16, 2025, Boston, MA

SAVE \$800 BY
REGISTERING
BEFORE
FRIDAY,
DECEMBER 13



12.30 Uncovering the Fundamentals for Manufacturing LNPs with Reliable Mixing, Filtration & Purification Techniques

- Delving into generic routes for scaling-up LNPs
- Uncovering the critical quality attributes which need to be considered to enable successful scale up
- Evaluating the currently strategies for mixing, filtering and purifying LNPs




1.00 Lunch & Networking


Unleashing the Huge Potential of LNPs to Encapsulate Many Payload Types for Developing Cures to a Large Disease Landscape

2.00 Panel Discussion: Leveraging LNPs to Deliver a Range of Payloads to Treat a Wide Landscape of Disease


- Highlighting the range of payloads being delivered by LNPs, including mRNA, siRNA, CAR DNA, gRNA and beyond
- Showcasing the different characteristics and specifications required to be met by LNPs to deliver the different payload types
- Uncovering the different challenges and opportunities it comes to using LNPs for both vaccines and therapeutics




Katherine Cook
Scientist II
Tessera Therapeutics



Kanika Suri
Scientist
Takeda Pharmaceuticals



Pintu Kanjilal
Scientist, LNP Discovery
Strand Therapeutics



3.00 Reviewing the Disease Applications of LNPs to Unleash their Full Potential for Treating a Large Variety of Patients

- Uncovering the potential of developing innovative LNPs for treating a wide landscape of disease
- Delving into the current clinical trials happening using LNPs to deliver genetic medicine, cell therapy, cancer and autoimmune treatments
- Discussing the bottlenecks faced when using LNPs for diseases outside of the liver

3.30 End of LNP 101 Day

■ ■ The summit is an exciting forum to discuss contemporary ideas in lipid nanoparticle formulation, characterization, and optimization for clinical development of nucleic acid therapeutics ■ ■

University Distinguished Professor, Northeastern University

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

11

+ (1) 617 455 4188 | info@hansonwade.com | www.lnp-formulation-process-development-pharma.com | LNP Development



Pre-Conference Day - Workshop Day

Monday, April 14

Snapshot of Expert Workshop Leaders:



Ching Kim Tye
Head, LNP Platform Development
Sanofi



Daniel Shores
Partner
Rothwell Figg



Jieni Xu
Head, Delivery Science
Editas Medicine

■ The summit provides a valuable space to foster collaborations, explore innovative solutions, and ultimately drive the development of more effective and efficient drug delivery systems ■

Head, Formulation, Zipcode Bio

4th Annual
**LNP Formulation &
Process Development Summit**
April 14-16, 2025, Boston, MA

Hear leading insights, expertise and case studies from LNP experts to overcome the greatest challenges within the LNP field. During deep-dive discussion-based content, attendees will interact and collaborate with subject matter experts to unlock essential strategies for accelerating LNPs from discovery to manufacturing.

Honing in on Four Key Areas:

- ➔ **Improving Lipid Libraries & High Throughput Screening Strategies for Improved Analysis of LNP Formulations**
- ➔ **Unlocking the Opportunity to Target Beyond the Liver by Delving into Strategies for Brain, Lung & Bone Marrow Targeting with Cell Specific LNPs**
- ➔ **De-Risking LNP CMC Development by Incorporating Risk Assessments & DoE Studies to Streamline Translation to GMP Manufacturing**
- ➔ **Navigating IP Challenges for Companies Utilizing Lipid Nanoparticle Delivery Systems to Enable Freedom to Operate & Mitigate Infringement Risk**



**SAVE \$800 BY
REGISTERING
BEFORE
FRIDAY,
DECEMBER 13**

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



**REGISTER
NOW**

12

+ (1) 617 455 4188

@ info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

in LNP Development



Pre-Conference Workshop Day | Monday, April 14

4th Annual
LNP Formulation &
Process Development Summit
April 14-16, 2025, Boston, MA

SAVE \$800 BY
REGISTERING
BEFORE
FRIDAY,
DECEMBER 13

8.50 Check-In & Coffee with Light Breakfast

Workshop A

9.00 Improving Lipid Libraries & High Throughput Screening Strategies for Improved Analysis of LNP Formulations

Identifying disease-relevant LNP formulations requires screening and testing many options, which can be time-consuming. In this workshop, we'll explore the opportunities for automation and collaboration to develop vast lipid libraries and high throughput-screening methods to fast-track more LNPs beyond discovery

- How to efficiently build and develop a large lipid library for high throughput screening
- How to create partnerships to enable sharing of lipid libraries
- How to mimic microfluidic mixing on very small scale to do high throughput screening of many LNP formulations
- How to incorporate AI/ML into HTS to improve understanding of structure-activity relationships



Bo Ying, Chief Executive Officer, **Abogen Biosciences**



Rajesh Krishnan, Senior Director, Formulation, **Providence Therapeutics**

Workshop C

9.00 De-Risking LNP CMC Development by Incorporating Risk Assessments & DoE Studies to Streamline Translation to GMP Manufacturing

To accelerate LNP translation to GMP manufacturing, integrating process development during the research phase is essential. This workshop will explore strategies to align payload and LNP manufacturing needs, ensuring a smoother drug development process.

- How to optimize each step of formulation to bridge gap between LNP and drug product development
- How to incorporate risk assessments earlier in the drug development pipeline to improve success of translation
- How to implement DoE studies into discovery and early research to understand the impact of each variable on the CMC development
- What considerations need to be carried out during payload discovery and LNP discovery to enable successful drug product production?



Srinivasulu Bandi, Director, External Manufacturing, **Sail Biomedicines**



Shengshuang Zhu, Senior Principal Scientist, **Arbor Biotechnologies**



Ching Kim Tye, Head, LNP Platform Development, **Sanofi**

12.00 Lunch & Networking

Workshop B

1.00 Unlocking the Opportunity to Target Beyond the Liver by Delving into Strategies for Brain, Lung & Bone Marrow Targeting with Cell Specific LNPs

LNPs are currently optimized for liver delivery, given their attractiveness to the APOE protein. During this workshop, you will delve into novel and innovative conjugations, customized lipids and alternative administration routes to enable delivery to the brain, lungs and bone marrow to treat a huge variation of diseases outside of the liver.

- Delving into targeting ligands for transporters on the BBB as strategies for brain targeting
- Deep diving into delivery mechanisms which enable successful targeting of the brain, lung and bone marrow
- How to improve drug accumulation at the target site and reduce clearance in the liver
- How to decorate LNPs with antibodies, nanobodies, peptides, proteins and more for enabling targeted extrahepatic delivery



Amit Singh, Director, Delivery Discovery, **RNA NewCo**



Mandana Borna, Head, Oligonucleotide Drug Product Development, **Biogen**



Jieni Xu, Head, Delivery Science, **Editas Medicine**

Workshop D

1.00 Navigating IP Challenges for Companies Utilizing Lipid Nanoparticle Delivery Systems to Enable Freedom to Operate & Mitigate Infringement Risk

As securing IP and avoiding patent infringements remain key challenges for the LNP community, this workshop will help you tackle these obstacles, strengthen your due diligence strategy, and enhance IP compliance.

- How to ensure you have high quality patent protection earlier in the drug development pipeline
- How to strategically identify lipids which are available to use which won't cause patent infringement
- Providing an overview of key freedom to operate challenges facing therapeutic developers operating in this space
- Covering advanced solution-based strategies for de-risking the therapeutic program from an IP perspective



Daniel Shores, Partner, **Rothwell Figg**

4.00 End of Workshop Day

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

13

+ (1) 617 455 4188

@ info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

LNP Development



Conference Day One

Tuesday, April 15

KEYNOTE SESSION:

Industry Leaders' Panel Discussion



Pieter Cullis
Professor
University of British Columbia



Annette Bak
Head, Advanced Drug Delivery
AstraZeneca



Sanyogitta Puri
Senior Director, Head, Non-Viral Delivery
Novo Nordisk



Magali Hickey
Head, LNP Process Development
Moderna



Muthiah (Mano) Manoharan
Senior Vice President, Innovation Chemistry
& Alnylam Distinguished Scientist
Alnylam Pharmaceuticals

Morning Plenary Session:

- ➔ Deep Diving into the Greatest Bottlenecks in the LNP Field

Analytical Development & Characterization Track

- ➔ Accomplishing Deeper Characterization for Understanding Targeted LNPs
- ➔ Improving Analytical Techniques for Assessing Quality, Stability & Encapsulation Efficiency
- ➔ Evaluating Lipid Properties & Excipient Quality

Formulation & Delivery Track

- ➔ Showcasing Successful Strategies for Improved Extrahepatic Targeting
- ➔ Achieving Muscle-Selective Delivery Through Customized Ionizable Lipids
- ➔ Achieving Greater Preclinical Efficacy & Safety for Accelerating Development of Potent LNP Formulations

Process Development & Manufacturing Track

- ➔ Developing Successful Late-Stage Manufacturing Strategies for Streamlined Translation
- ➔ Identifying Key Considerations to Scale-Up LNP Manufacturing
- ➔ Accelerating LNP Production with Advanced Manufacturing Strategies



SAVE \$800 BY
REGISTERING
BEFORE
FRIDAY,
DECEMBER 13

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

Conference Day One | Tuesday, April 15

4th Annual
LNP Formulation &
Process Development Summit
April 14-16, 2025, Boston, MA

SAVE \$800 BY
REGISTERING
BEFORE
FRIDAY,
DECEMBER 13

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS

REGISTER
NOW



7.15 Check-In & Coffee with Light Breakfast

8.15 Chair's Opening Remarks

Deep Diving into the Greatest Bottlenecks in the LNP Field to Improve Dosing, Scaling & Delivery for Advancing More LNPs Towards Approval

8.30 Industry Leaders' Panel Discussion: Overcoming the Challenges of Toxicity, Extrahepatic Delivery & Scaling-Up in LNP Development to Accelerate a Wider Range of Therapeutics towards the Clinic

- What strategies are you implementing to enable greater cell specific delivery to targets outside of the liver?
- How does analytical development and manufacturing change for targeted LNPs to enable scale-up?
- What methods do you have in place to face the challenge of toxicity?



Pieter Cullis
Professor
University of British
Columbia



Annette Bak
Head, Advanced Drug
Delivery
AstraZeneca



Sanyogitta Puri
Senior Director, Head,
Non-Viral Delivery
Novo Nordisk



Magali Hickey
Head, LNP Process
Development
Moderna



Muthiah (Mano) Manoharan
Senior Vice President, Innovation Chemistry
& Alnylam Distinguished Scientist
Alnylam Pharmaceuticals



Pieter Cullis
Professor
University of British
Columbia

9.00 Unlocking the Future of LNPs for Delivery of a Wide Range of Human Medicines

- Delving into the LNP landscape to unleash the latest and greatest LNPs in the field
- Addressing key bottlenecks which the LNP field is facing, including advancing LNPs for successful gene therapy delivery
- Uncovering the future potential for LNPs to deliver more human medicines



9.30 Session Reserved for Serina Therapeutics



10.00 Morning Break & Speed Networking

This session is your opportunity to get face-to-face with many of the brightest minds working in the LNP field and establish meaningful business relationships to pursue for the rest of the conference. Also, don't forget to enjoy some refreshments before we split off into the 3 different tracks: Analytical Development & Characterization, Formulation & Delivery & Process Development & Manufacturing

15

+ (1) 617 455 4188

@ info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

LNP Development



Track A - Analytical Development & Characterization

Accomplishing Deeper Characterization with Improved Particle Analysis for Understanding LNP Surface Changes & Targeting Moieties

CHAIR - Anni Chang, Senior Scientist II, Excipients GSSD, US Pharmacopeia

11.00 Understanding the Distribution, Function, & Impact of Targeting Moieties for Deeper Characterization of Targeted LNPs (tLNPs)

- Characterizing the distribution of targeting moieties on tLNPs
- Strategies to assess the function of targeting moieties on tLNPs
- Interrogating how conjugation impacts tLNP properties



David Chu, Senior Director, Analytical Development, Capstan Therapeutics

NEW DATA

11.30 Roundtable Discussion: Delving into Flow Imaging Techniques for Enabling Single Particle Analysis to Better Characterize LNPs

- How to automate single particle analysis to make it more time efficient
- How to use single particle analysis for deeper analysis into particle size and encapsulation efficiency
- How do changes in the process affect each individual particle?



12.00 Heightened Characterization Strategies of mRNA/LNPs & the Power of NMR

- Heightened Characterization Roadmap for mRNA/LNP Modalities
- How NMR can support LNP Characterization
- A case study demonstrating how NMR can detect surface LNP changes



Erika Jensen, Principal Scientist, Pfizer

NEW DATA

12.30 Lunch Break & Networking

Improving Analytical Techniques for Assessing Quality, Stability & Encapsulation Efficiency Leading to Reduced Toxicity Challenges

1.30 Analytical Strategies to Understand LNP Quality & Stability

- Implementing MALs and HPLC into the analytical strategy for improved monitoring of LNPs
- Showcasing novel analytical methods have been developed to understand stability and predict shelf-life for targeted LNPs
- Evaluating assays which can be used to understand the degradation mechanisms of LNPs



Felipe Gazos Lopes, Associate Director, Analytical Development, Tessera Therapeutics

2.00 Session Reserved for Partner

- Enquire Now -Sponsor@hansonwade.com

2.30 Emerging Methods to Determine Encapsulation Efficiency of Large Payloads in LNP

- Overcoming the challenges of measuring encapsulation in LNPs to ensure the payload is successfully loaded
- Delving into emerging methods for determining encapsulation efficiency
- Showcasing an optimized Ribogreen assay for more accurate measurement of LNP encapsulation



Swathi Pullagurta, Senior Scientist, Gritstone Bio

NEW DATA

3.00 Afternoon Networking Break & Scientific Poster Session

Contribute to the conversation and share your cutting-edge research with your fellow LNP community to showcase your breakthrough discoveries to a vast audience of experts. Register your place to submit an abstract for review to showcase your poster*

*Please visit the website for the T&Cs for presenting a poster

Evaluating Lipid Properties & Excipient Quality to Understand Key Parameters for Advancing High Quality & Stable LNPs

4.00 Delving into the Physicochemical Properties of Lipids to Improve Product Performance & Shelf-Life

- Uncovering strategies for deeper characterization of lipids to understand their impact on the final product
- Showcasing the impact of the lipid component on shelf-life and shear thinning/thickening
- Highlighting what we are yet to learn about the lipids for complete understanding



Magali Hickey, Head, LNP Process Development, Moderna

4.30 Showcasing USP's Perspective on New Frontiers in Excipient Quality & Development, including for Developing Safe & Compliant LNPs

- Reviewing USP's perspective on excipient quality and development
- Discussing opportunities for incorporating lactide (or lactic acid) and glycolide (or glycolic acid) (LG) polymers in nanoparticles for improved delivery of therapeutics and vaccines
- Highlighting USP's work on phospholipids and providing new updates



Peng Zhang, Principal Scientist, US Pharmacopeia

5.00 Ask the Speakers

Your unique opportunity to ask the speakers your burning questions from the previous sessions in a dedicated Q&A session.

5.30 Chair's Closing Remarks

5.45 LNP Awards & Drinks Reception

CONTENTS

INTRODUCTION

AGENDA AT A GLANCE

YOUR EXPERT SPEAKERS

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PRICING & DISCOUNTS



REGISTER NOW

Track B - Formulation & Delivery

Showcasing Successful Strategies to Reduce Liver Clearance & Involve Endogenous Mechanisms for Improved Extrahepatic Targeting

CHAIR - Sanyogitta Puri, Senior Director, Head, Non-Viral Delivery, **Novo Nordisk**

11.00 Endogenous Mechanisms for Targeted Delivery of Nucleic Acid Therapy with Lipid Nanoparticles

- Showcasing strategies for engineering LNPs to attract proteins to enhance extrahepatic delivery
- Using immune cells to deliver LNPs to the target sites to enable cell-specific targeting
- Enhancing bystander effect by delivering LNPs and encouraging production of exosomes to increase density of delivery to cells in the area



Mansoor Amiji, University Distinguished Professor, **Northeastern University**

11.30 Session Details to Be Revealed



12.00 Improving Formulation & Design of Targeted LNPs to Unlock the Potential of Extrahepatic Delivery

- Delving into strategies for reducing liver tropism and toxicity of targeted LNPs
- Uncovering improved formulations for better stability and greater shelf life
- Optimizing and characterizing tLNPs for enabling cell specific delivery



Bo Ying, Chief Executive Officer, **Abogen Biosciences**

NEW DATA

12.30 Lunch Break & Networking

Achieving Muscle-Selective Delivery Through Customized Ionizable Lipids to Develop Vaccines Against More Diseases

1.30 Discovery of Novel Ionizable Lipids for the Intramuscular Delivery of mRNA Vaccines

- A general overview on LNP based mRNA delivery system for the development of mRNA vaccine platform
- Design and synthesis of novel ionizable lipids for the efficient delivery of mRNA vaccines
- Focus on building Structure Activity Relationship (SAR) of novel ionizable lipids with improved immunogenicity and reduced reactogenicity towards the development of effective mRNA vaccines



Saswata Karmakar, Director, Chemistry, **Sanofi**



NEW DATA

2.00 Session Details to Be Revealed



2.30 Muscle-Selective Ionizable Lipid-Based mRNA-LNP & their Applications in Novel Vaccine Development

- Muscle-selective gene delivery by novel ionizable lipid-based LNP
- Enhanced safety through minimized systemic exposure
- Promising vaccination efficacy against various infectious diseases



Jee-Young Park, Executive Director, **MediciBIO**



NEW DATA

3.00 Afternoon Networking Break & Scientific Poster Session

Contribute to the conversation and share your cutting-edge research with your fellow LNP community to showcase your breakthrough discoveries to a vast audience of experts. Register your place to submit an abstract for review to showcase your poster*

*Please visit the website for the T&Cs for presenting a poster

Optimizing *In Vitro* to *In Vivo* Translation to Improve Preclinical Efficacy & Safety for Accelerating Potent LNP Formulations

4.00 Optimizing Tissue Distribution & Safety of LNP-Mediated Prophylactic Vaccines to Accelerate Prevention of Infection & Disease

- Preclinical immunogenicity and efficacy of prophylactic vaccines
- Tissue distribution and safety profile of prophylactic vaccines
- Preclinical efficacy study of mRNA-based protein replacement therapy for rare disease(s)



Hui Li, Research & Development Director, **Innorna**

NEW DATA

4.30 Session Details to Be Revealed



5.00 Pre-Clinical Efficacy of a Novel Anti-GPC3 *In Vivo* CAR-M for Hepatocellular Carcinoma

- Identify an LNP encapsulated mRNA encoding anti-GPC3 CAR that induces GPC3 antigen-driven macrophage activation and anti-tumor activity
- Demonstrate pre-clinical anti-tumor efficacy *in vivo* by systemically delivering LNP encapsulated mRNA encoding CAR targeting GPC3.



Bindu Varghese, Executive Director, Research, **Carisma Therapeutics**

NEW COMPANY

5.30 Chair's Closing Remarks

5.45 LNP Awards & Drinks Reception

CONTENTS

INTRODUCTION

AGENDA AT A GLANCE

YOUR EXPERT SPEAKERS

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PRICING & DISCOUNTS



REGISTER NOW

Track C - Process Development & Manufacturing

Optimizing Process Development to Develop Successful Late-Stage Manufacturing Strategies for Streamlined Translation

CHAIR - Alexey Popov, Vice President, Head, Process Development, **Sail Biomedicines**

11.00 Developing a Successful Phase 1 Manufacturing Strategy for an mRNA-Based Cancer Vaccine

- Developing novel lipids and LNPs for mRNA cancer vaccines
- Development of drug product
- Tech transfer and scale-up of lipids, mRNA and mRNA-LNPs



Rajesh Krishnan, Senior Director, Formulation, **Providence Therapeutics**

NEW DATA

NEW COMPANY

11.30 Session Details to Be Revealed



12.00 Process Characterization & Gap Analysis Considerations for Phase III Readiness

- What should be key considerations be in the process understanding assessment?
- Defining robustness and scalability early allows more opportunities to systematically design and characterize an efficient and effective process
- Implementing platform approaches to process design and development



Ami Jo, Associate Director, Process Development, **Omega Therapeutics**

NEW DATA

NEW COMPANY

12.30 Lunch Break & Networking

Identifying Key Considerations to Scale-Up LNP Manufacturing Leading to Reduced Variation Across Batches

1.30 Optimizing Formulation & Early Process Development Strategies to Enable Scale-Up of Novel LNPs

- Sharing new and innovative formulations for novel LNPs which are thermostable and PEG free
- Translating these new LNP formulations to early process development with optimized manufacturing and scalability
- Showcasing a proof of concept of scaling-up a proprietary LNP platform



George Dakwar, Director, Formulation Platform, **CureVac**

2.00 Session Details to Be Revealed



2.30 Identifying Critical Parameters & Considerations for Successful Scale-Up of LNPs

- Discussing key parameters and variables which need to be considered when scaling-up LNP production and optimizing process development
- Evaluating how *in vitro* testing and animal study results change when you go from small scale LNP production to large scale
- Uncovering how equipment selection impacts formulation



Alexey Popov, Vice President, Head, Process Development, **Sail Biomedicines**

NEW DATA

NEW COMPANY

3.00 Afternoon Networking Break & Scientific Poster Session

Contribute to the conversation and share your cutting-edge research with your fellow LNP community to showcase your breakthrough discoveries to a vast audience of experts. Register your place to submit an abstract for review to showcase your poster*

*Please visit the website for the T&Cs for presenting a poster

Accelerating LNP Production with Optimized Process & Advanced Manufacturing Strategies

4.00 Process Optimization for Gene Therapy LNP Production Via Design of Experiment

- Identification of Critical Process Parameters via DoE (Design of Experiment)
- Filling the gap between processability and biological potency
- Scaling-up tech transfer, small scale to large scale

NEW DATA



Gook Lee, Research Advisor, **Eli Lilly & Co**

4.30 Uncovering Advanced Strategies for Continuous Manufacturing to Accelerate Production of LNPs

- Showcasing what continuous manufacturing is for LNPs to fast-track their production
- Unleashing the advantages of continuous advanced manufacturing over traditional manufacturing processes
- Uncovering the impact of continuous manufacturing on stability and real-time analysis of the LNPs



Diane Burgess, Distinguished Professor, **University of Connecticut**

NEW DATA

5.00 Ask the Speakers

Your unique opportunity to ask the speakers your burning questions from the previous sessions in a dedicated Q&A session.

5.30 Chair's Closing Remarks

5.45 LNP Awards & Drinks Reception

CONTENTS

INTRODUCTION

AGENDA AT A GLANCE

YOUR EXPERT SPEAKERS

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PRICING & DISCOUNTS



REGISTER NOW

Conference Day Two

Wednesday, April 16

KEYNOTE SESSION:

Forging New Alliances in the LNP Industry with Strategic Partnerships & Collaborative Opportunities



Benjamin Frempah
Director, Business Development
Omega Therapeutics



John Lewis
Chief Executive Officer
Entos Pharmaceuticals



Anubhav Arora
Director, Chemistry, Manufacturing & Controls
Apellis Pharmaceuticals

■ This event will provide an invaluable overview of the current industry landscape and emerging trends in LNP technology. ■

Scientist, **Takeda Pharmaceuticals**

Morning Plenary Session:

- ➔ Uncovering Opportunities for Partnering, Collaborating & Licensing to Fast-Track Efficacious & Cell Specific LNPs

Analytical Development & Characterization Track

- ➔ Improving LNP Potency Using Cryo-EM & Assay Methods
- ➔ Standardizing Analytical Development for LNPs to Create a Clear & Robust Roadmap for Drug Developers

Formulation & Delivery Track

- ➔ Shining a Spotlight on Innovative LNP Formulations to Improve Encapsulation of Gene Editors & Overcome Toxicity
- ➔ Illuminating the Potential of LNPs for Gene Editors & Delving into Genuine Clinical Trial Data

Process Development & Manufacturing Track

- ➔ Delving into Strategies for Improving Stability & Storage of LNPs
- ➔ Accomplishing LNP Thermostability to Enable Global Availability of Efficacious LNP-Mediated Therapies

Closing Plenary Session:

- ➔ The Future of LNPs: Illuminating Next Generation LNPs

SAVE \$800 BY
REGISTERING
BEFORE
FRIDAY,
DECEMBER 13

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

Conference Day Two | Wednesday, April 16

4th Annual
LNP Formulation &
Process Development Summit
April 14-16, 2025, Boston, MA

SAVE \$800 BY
REGISTERING
BEFORE
FRIDAY,
DECEMBER 13



7.15 Check-In & Coffee with Light Breakfast

8.15 Chair's Opening Remarks

Uncovering Opportunities for Partnering, Collaborating & Licensing to Fast-Track Efficacious & Cell Specific LNPs Towards the Patients in Need

8.30 Panel Discussion: Forging New Alliances in the LNP Industry with Strategic Partnerships & Collaborative Opportunities to Accelerate More LNPs onto the Market

- How to identify complementary strengths and weaknesses in other biopharma companies to optimize partnership capabilities
- How to decide who invests in which resources and who gains which returns
- What thought processes and strategies should be put in place for determining successful partnerships between biotech/biotech and biotech/pharma?



Benjamin Frempah
Director, Business
Development
Omega Therapeutics



John Lewis
Chief Executive Officer
**Entos
Pharmaceuticals**



Anubhav Arora
Director, Chemistry,
Manufacturing & Controls
Apellis Pharmaceuticals



Benjamin Frempah
Director, Business
Development
Omega Therapeutics

9.00 Navigating Licensing Agreement Challenges to Capitalize on Using More Novel Lipids for Improved Targeted Delivery

- Effectively navigating deal terms to ensure accomplishment of partnership goals
- Showcasing strategies for accelerating to the final point in the transaction process
- Aligning the key economics and qualities of a good licensing partnership to enable commercial success on both sides of the deal



9.30 Session Reserved for ReciBioPharm



10.00 Morning Networking Break

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

20

+ (1) 617 455 4188

@ info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

LNP Development



Track A - Analytical Development & Characterization

Improving LNP Potency Using Cryo-EM & Assay Methods to Accelerate more Biologically Relevant LNPs towards Approval

11.00 Optimizing LNP Analysis using Small Angle X-Ray Scattering, Cryo-EM & LNP Research-Grade Test Materials for More Efficacious Therapeutics

- Leveraging Small small angle x-ray scattering for understanding the relationship between LNP formulation and structure
- Coupling small angle x-ray scattering and Cryo-EM for improved LNP analysis
- Producing, homogeneity testing and characterizing of a NIST LNP/RNA research-grade test material



Thomas Cleveland, Research Physicist, NIST

NEW DATA

11.30 Delving into Potency Assay Strategies for LNP-mRNA Therapies to Enable Accurate Potency & Efficacy Testing for Rare Diseases

- Challenges of developing functional assays for rare diseases
- Phase appropriate strategy for potency assay development
- Controlling variability in cell-based potency assay



Rumpa Bhattacharjee, Senior Scientist II, ReCode Therapeutics

12.00 Lunch Break & Networking

Standardizing Analytical Development for LNPs to Create a Clear & Robust Roadmap for Drug Developers Leading to More Regulatory Compliant LNPs

1.00 Delving into Gaps of LNP Characterization to Achieve Improved Nucleic Acid Delivery

- Evaluating advanced tools used for deeper characterization of LNP delivery vehicles
- Discussing how to better inform design of these LNPs using various advanced characterization tools
- Bridging the gaps for improved understanding of LNP characteristics for designing more effective delivery systems



Yan Xia, Head, Nanotechnology Formulations, Axelyf

1.30 Session Details to Be Revealed



1.45 Roundtable Discussion: Defining an LNP Analytical Roadmap to Standardize Testing Methods for Full Characterization of LNPs

- How to analyze LNP size and encapsulation of payload to minimize heterogeneity
- How to identify orthogonal analytical testing strategies to gain whole LNP understanding
- How to gain both qualitative and quantitative data for deeper understanding of how many LNPs have payload completely encapsulated



Erika Jensen, Principal Scientist, Pfizer



Sudhakar Garad, Global Head, Pre-formulation, Novel Delivery & Biopharmaceuticals, Novartis

2.15 Afternoon Networking Break

Track B - Formulation & Delivery

Shining a Spotlight on Innovative LNP Formulations to Improve Encapsulation of Gene Editors & Overcome Toxicity

CHAIR - George Dakwar, Director, Formulation Platform, **CureVac**

11.00 Maximizing LNPs Therapeutic Potential by Optimizing Formulation for Gene Editing Payloads

- Enabling cell specific delivery of gene editing machinery using novel and innovative LNP formulations
- Uncovering *in vivo* testing strategies to enable dosing gene editing therapies



Shengshuang Zhu, Senior Principal Scientist, **Arbor Biotechnologies**

NEW COMPANY

11.30 Novel Triple-Payload LNPs for Ex-Vivo Gene-Editing

- A novel formulation process generated LNPs with three nucleic acid modalities – sgRNA, mRNA and DNA – for CRISPR-mediated genome editing of human T cells
- Gene-editing efficiency was dependent on both payload and lipid design factors
- LNP-generated CAR T cells demonstrated remarkable pharmacological activity



Melissa Hanson, Senior Principal Scientist, **Bristol Myers Squibb**



NEW DATA

12.00 Lunch Break & Networking

Illuminating the Potential of LNPs for Gene Editors & Delving into Genuine Clinical Trial Data to Advance Safe & Efficacious LNPs

1.00 LNP-Mediated *In Vivo* Genome Editing: Translating Science from Bench to Bedside

- Introducing our proprietary lipid nanoparticle (LNP) mediated delivery systems targeting both liver and HSCs in the bone marrow
- Interim clinical updates on YOLT-201, YOLT-101 and YOLT-203 *in vivo* genome editing programs will be discussed



Zi Jun Emma Wang, Chief Technology Officer, **Yoltech Therapeutics**

NEW COMPANY

NEW DATA

1.30 Session Details to Be Revealed

JenKem® JenKem Technology USA
Serving Your PEGylation Needs From Laboratory Through Commercial Scale

1.45 LNP-RNA Powered Prime Editing for the Treatment of Genetic Diseases

- Introducing Prime Editing and how Prime Medicine is engineering Prime Editors and using RNA to improve Prime Editing outcomes
- How Prime Medicine is building its RNA, delivery, and manufacturing platforms to enable Prime editing
- Specific examples of *in vivo* data demonstrating the potential and application of RNA-powered Prime Editing in treating particular genetic diseases and the future of technology



Luis Santos, Senior Director, **Prime Medicine**



2.15 Afternoon Networking Break

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

Track C - Process Development & Manufacturing

Delving into Strategies for Improving Stability & Storage of LNPs to Enable Global Access to LNP-Based Therapies

CHAIR - Rajesh Krishnan, Senior Director, Formulation, **Providence Therapeutics**

11.00 Nuances of Lyophilized Lipid Nanoparticles

- Examining the challenges with mRNA LNP liquid formulations
- Evaluating the potential of lyophilization for improving the stability of LNPs
- Weighing the impact of lyophilization on LNP critical quality attributes



Sashini Wijetunge, Senior Scientist, **Pfizer**

NEW DATA

11.30 Thin-Film Freeze-Drying of mRNA-Lipid Nanoparticles

- Showcasing thin-film freeze-drying (TFFD) which is a bottom-up powder- and particle-engineering technology with intermediate freezing rates and unique mass and heat transfer mechanisms
- Uncovering how TFFD was successfully applied to prepare dry powders of mRNA-LNPs with various nanostructures
- Evaluating the potential of TFFD to enable long-term storage of mRNA-LNPs in non-freezing conditions



Zhengrong Cui, Professor, **The University of Texas at Austin**

NEW DATA

12.00 Lunch Break & Networking

Accomplishing LNP Thermostability for Improved Storage to Enable Global Availability of Efficacious LNP-Mediated Therapies

1.00 Strategy for the Development of Thermostable mRNA Vaccines

- The importance of thermostable drug product profile for mRNA vaccines
- Strategy for development of thermostable mRNA vaccines
- The formulation factors consideration during the thermostable product development



Ching Kim Tye, Head, LNP Platform Development, **Sanofi**

1.30 Session Reserved for Innovation Partner

- Enquire here - Sponsor@hansonwade.com

Opportunity for Partnership

1.45 Fireside Chat: Navigating LNP Thermostability Challenges to Improve Storage & Minimize Impact to LNP Efficacy

- How to improve LNP thermostability by changing formulation
- How to improve the time and cost impacts involved when adding lyophilization to your manufacturing process
- How does freezing LNPs affect LNP therapeutic ability due to structure changes after a long period of time?



Ching Kim Tye, Head, LNP Platform Development, **Sanofi**



Zhengrong Cui, Professor, **The University of Texas at Austin**



2.15 Afternoon Networking Break

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO


PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

The Future of LNPs: Illuminating Next Generation LNPs for Delivering Nucleic Acid Therapies to the Patients in Need




John Lewis
Chief Executive Officer
Entos Pharmaceuticals

3.00 Beyond the liver: Engineering the Fusogenix PLV Platform for Extra-Hepatic Delivery of RNA & DNA

NEW DATA

NEW COMPANY

- Development of a fusion-powered delivery system for RNA and DNA
- Optimization of formulation to achieve extra-hepatic delivery with maximum tolerability
- PLV-mediated delivery of RNA and DNA to tissues and cells of the lung, eye, and muscle



Jie Su
Head, Formulation
Zipcode Bio

3.30 Development of SHARP: A Novel Next-Generation Non-Viral Delivery Technology for mRNA

NEW DATA

NEW COMPANY

- The innovative SHARP (Single-component Homogeneous Amphiphilic Routed Particles) delivery technology demonstrates exceptional stability comparing to the four-component lipid nanoparticle systems
- SHARP technology paves the way for functionally delivering nucleic acids beyond the conventional lipid nanoparticle systems
- SHARP efficiently delivers mRNA cargo to liver as well as to extrahepatic organs

4.00 Chair's Closing Remarks

4.15 End of 4th LNP Formulation & Process Development Summit 2025

▀▀ Being able to participate in such discussions and learn different perspectives on current challenges in LNPs will help me design better drug products for the patients. ▀▀

Scientist, LNP Discovery, Strand Therapeutics

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

Why Our Expert Speakers are Excited About 2025

4th Annual LNP Formulation & Process Development Summit

April 14-16, 2025, Boston, MA

SAVE \$800 BY REGISTERING BEFORE FRIDAY, DECEMBER 13



“This meeting is an excellent opportunity to connect with my counterparts in the biotech community and learn about the latest progress and challenges in advancing LNPs”

Alexey Popov, Vice President, Head, Process Development, Sail Biomedicines



“I have always enjoyed participating in this meeting because it brings together the thought leaders in the field of LNP early discovery, PD and scale-up”

Amit Sing, Director, Delivery Discovery, RNA NewCo



“This kind of collaboration not only accelerates progress within our respective areas but also helps in shaping the future of drug delivery and therapeutic development”

Mandana Borna, Head, Oligonucleotide Drug Product Development, Biogen



“LNP is crucial for the success of RNA-based therapeutics, however, the development and characterizations of LNP has always been challenging given that it is a complex system. There are more know-hows than patents in the field, therefore, I look forward to more discussions with peers in the field”

Bo Ying, Chief Executive Officer, Abogen Biosciences



“Attending the 4th LNP Formulation & Process Development Summit provides significant value. It offers an excellent platform for engaging with experts and discussing the latest advancements in LNP technology”

Jivan Yewle, Director Non-Viral Delivery, Mammoth Biosciences



“For professionals interested in deepening their understanding of lipid nanoparticles (LNPs) or seeking a comprehensive update in this field, I highly recommend attending this conference”

Kanika Suri, Scientist, Takeda Pharmaceuticals



2025 Expert Partners

4th Annual
LNP Formulation &
Process Development Summit
April 14-16, 2025, Boston, MA

SAVE \$800 BY
REGISTERING
BEFORE
FRIDAY,
DECEMBER 13

Lead Partner



Expertise Partner



Program Partners



Innovation Partners



Exhibition Partners



CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

Partner With Us - Take the Spotlight

Your Platform to Showcase Your Exclusive Services & Foster New Relationships within the Rapidly Growing LNP Space

With over 300 LNP experts from innovative biotech, established biopharma and large pharma landing in Boston for the 4th LNP Formulation & Process Development Summit, this is your definitive forum to elevate your brand and expertise to a community searching for long-term partners to supercharge their LNP development.

Benefits of Partnering:

- Thought Leadership:** Grab the spotlight by presenting your work within one of our focused tracks or participate in a panel discussion to demonstrate your team's expertise and knowhow
- Benefit From Marketing Intelligence:** With many new LNP formulations being explored, hear how and where biopharma are searching for services and solutions to facilitate their R&D efforts and match your premium offerings accordingly
- Meet & Network In-Person with Industry Pioneers:** With a room full of drug developers from the likes of AstraZeneca, Moderna, CureVac, Novo Nordisk, Omega Therapeutics, Sanofi and more, meet prospective clients during dedicated networking breaks to fuel commercial opportunities
- Raise Brand Awareness & Generate Commercial Collaborations:** Benefit from pre-and post- conference exposure to our comprehensive LNP community and increase market share through unique branding formats

Our Audience are Looking for Partners Including:

 CDMO	 Lipid Suppliers	 Analytical & Process Development Equipment	 Formulation & Synthesis
 Particle Engineering & Characterization	 Imaging & Bioinformatics	 High Throughput Screening & Lipid Libraries	 Consultancy



Nicholas Ramovic
Senior Partnerships Director
Tel: +(1) 617 455 4188
Email: sponsor@hansonwade.com




Jack Marcus
Senior Partnerships Director
Tel: +(1) 617 455 4188
Email: sponsor@hansonwade.com


4th Annual LNP Formulation & Process Development Summit
April 14-16, 2025, Boston, MA

SAVE \$800 BY REGISTERING BEFORE FRIDAY, DECEMBER 13

Audience Geo*:



Audience Seniority*:



*Stats Based on the 3rd LNP Formulation & Process Development Summit

CONTENTS

INTRODUCTION

AGENDA AT A GLANCE

YOUR EXPERT SPEAKERS

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PRICING & DISCOUNTS



REGISTER NOW

Ready to Register?

3 Easy Ways To Book



www.lnp-formulation-process-development-pharma.com/take-part/register



Tel: (+1) 617 455 4188



Email: info@hansonwade.com

Team Discounts*

- 10% discount – 3 Attendees
- 15% discount – 4 Attendees
- 20% discount – 5+ Attendees

*Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

- 1 **Unparalleled** access LNP industry leader's insights from **Moderna, AstraZeneca, Novo Nordisk, Alnylam & University of British Columbia** to guide your pipeline direction
- 2 **Network** with **300+ LNP experts** bound by the same challenges across and hurdles across Analytical Development, Formulation, Process Development & Manufacturing
- 3 **Divide** and conquer 3 days of content and 3 track program spanning the end-to-end development of LNPs, from discovery through to clinic

SAVE \$800 BY REGISTERING BEFORE FRIDAY, DECEMBER 13

CONTENTS

INTRODUCTION

AGENDA AT A GLANCE

YOUR EXPERT SPEAKERS

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PRICING & DISCOUNTS

Drug Developer Pricing**	Register & Pay By Friday, December 13	On the Door	Academic Pricing**	Register & Pay By Friday, December 13	On the Door	Solution Provider Pricing	Register & Pay By Friday, December 13	On the Door
FULL ACCESS PASS: Conference + Workshop Day OR LNP 101 Day	\$3,597 (Save \$800)	\$4,397	FULL ACCESS PASS: Conference + Workshop Day OR LNP 101 Day	\$2,997 (Save \$800)	\$3,797	FULL ACCESS PASS: Conference + Workshop Day OR LNP 101 Day	\$4,497 (Save \$800)	\$5,297
Conference Only	\$2,699 (Save \$500)	\$3,199	Conference Only	\$2,299 (Save \$500)	\$2,799	Conference Only	\$3,399 (Save \$500)	\$3,899

**To qualify for the drug developer rate your company must have a public drug pipeline and not offer fee-based services.

***To qualify for academic rate you must be full time academic. Do you work for a Not-for-Profit organization? Please visit the website for full pricing options or email info@hansonwade.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom

Venue

The Westin Copley Place

10 Huntington Avenue, Boston, MA 02116, United States

www.marriott.com/en-us/hotels/boswi-the-westin-copley-place-boston/overview/



REGISTER NOW

28

+ (1) 617 455 4188

@ info@hansonwade.com

🌐 www.lnp-formulation-process-development-pharma.com

in LNP Development

